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We fully agree with the basic statement by Mehta
et al. [1] that the conventional method used so far, for
validation of surrogate markers has an intrinsic limita-
tion, because the reference standard, in this case liver
biopsy, is imperfect in regard to the prediction of the
disease. In chronic hepatitis C core fragments of
40 mm have a 25% rate of misclassiﬁcation of META-
VIR stages [2]. Ironically, striving for the highest AUR-
OC will only result in a test having the same high rate of
misclassiﬁcation vs. the presence of the disease. Depend-
ing on the prevalence of the disease and the sensitivity
and speciﬁcity of liver biopsy, a surrogate with a lower
AUROC might provide a better prediction of the disease
than one with a higher AUROC. Another rational con-
sequence is that studies observing 100% AUROC for
any biomarker validated with biopsy are either under-
powered or faked.
Consequently Mehta et al. correctly suggest that new
methodology is needed given the lack of a perfect refer-
ence standard. Clinical discussion of discordance cases
and exclusion of spectrum bias are examples of such
new methods [2]. Spectrum bias is a signiﬁcant con-
founder of AUROC and that diﬀerences in prevalence
of stages deﬁning advanced or non-advanced ﬁbrosis (or
deﬁning non-cirrhosis versus cirrhosis) can explain vari-
ability of AUROCs for the same test when performed in
diﬀerent populations [2]. We believe this is the reason
why ‘‘changing the deﬁnition of diseased liver from F4
to F2F3F4 is associated with a decrease in the AUROC
for a biomarker” and not because the biomarker is ‘‘not
adequate” as stated in the accompanying editorial [3].
We have shown that anAUROCof 0.90 for F4, anAUR-
OC of 0.80 for F2F3F4 and an AUROC of 0.65 for the
distinction between F1 and F2 are all similarly ‘‘ade-
quate” [2]. Remarkably, this is true for any diagnostic test
including liver biopsy. When compared to the real gold
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nization Assistance Publique Hoˆpitaux de Paris.plays similarly reduced AUROCs for the distinction of
adjacent ﬁbrosis stages (e.g. F1 vs. F2) than for distant/
end of spectrum stages [2]. Biomarkers or biopsy do not
perform any diﬀerently in that regard.
Bedossa and Carrat state that serum markers have
been developed to provide a binary assessment of ad-
vanced vs. non-advanced ﬁbrosis which they perceive
as limited and insuﬃciently informative [3]. It is worth
pointing out that this pragmatic separation has been
widely adopted by the FDA, the EMEA and multiple
medical society guidelines. However we do agree that
with surrogate markers, a further step needs to be taken,
both in terms of information provided by these and val-
idation vs. hard clinical end points. For instance, in an
attempt to validate FibroTest independent of the imper-
fect reference standard (liver biopsy), we tested it using
repeated measurements, the impact of eﬀective treat-
ment and prognostic value [2]. In line with what Mehta
et al. proposed, three prognostic validations of Fibro-
Test in viral hepatitis C, B and alcoholic liver disease
have been performed [2,4,5] and similar data with other
biomarkers will certainly follow. Therefore we strongly
refute the editorial’s claim that ‘‘because of the condi-
tional relationship with liver biopsy, serum markers
might represent a dead end” [3]. We rather side with
Mehta et al.’s quite opposing view that attempts to val-
idate markers are limited by imperfections of liver
biopsy when taken as the reference standard. Contrarily
to the editorialist’s statement, the other frequent liver in-
jury such as activity, steatosis, NASH and alcoholic hep-
atitis can be diagnosed with available biomarkers [2].
We fully agree with Mehta et al. that new methodo-
logical developments are needed, speciﬁcally designed
for comparing estimates such as biopsy or biomarkers,
without using any gold standard. For instance, factors
associated with false-positive or false-negative of ﬁbrosis
biomarkers can be identiﬁed without using biopsy [6].
But beyond these methodological considerations,
there are some basic issues when discussing the use of li-
ver biopsy versus that of surrogate non-invasive mark-
ers. The editorial totally overlooked the risk-beneﬁt
ratio of the diﬀerent diagnostic tests. In 2007, two deaths
attributable to liver biopsy were reported to a nationwide
malpractice insurance company: one in chronic hepatitis
C and another in primary biliary cirrhosis [7]. We devel-
oped research on biomarkers in order to prevent these
and other serious side eﬀects. Given the increasing inci-
dence and mortality of some liver diseases, screening
for advanced ﬁbrosis in the general population is a major
public health challenge. This can only be achieved
through a moratorium on liver biopsy as a ﬁrst-line esti-
mate of injury in chronic liver diseases and the validation
of non-invasive markers [8]. While we agree that liver
biopsy (of 40 mm) remains the best reference standard,
it should only be used when all available non-invasive
methods have failed to convince the clinician.
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Liver ﬁbrosis: Screening is not staging
To the Editor:
The letter by Poynard and colleagues deserves several
comments. Like Mehta et al., we agree that when taking
liver biopsy as a reference, any non-invasive test should
not reach a higher AUROC than the liver biopsy itself,
mainly due to the fact that misclassiﬁcation can occur in
staging ﬁbrosis with biopsy [1,2]. The highest AUROC
that can be reached is however unclear and clearly depen-
dent on (1) the rate of misclassiﬁcation in staging with
biopsy (2) the conditional relationship between non-inva-
sive markers and liver histology (3) the internal perfor-
mance of the marker. Interestingly, a recent meta-
analysis of Fibroscan showed AUROC of 0.94 for diag-
nosis of cirrhosis and 0.89 for severe ﬁbrosis taking biopsy
as a reference [3]. These very highAUROCvalues are cer-
tainly not related to a lack of power (more than 10,000 pa-
tients were pooled) or faking as suggested by Poynard
et al. It simply demonstrates that liver biopsy is an accept-
able gold standard and that some, but not all non-invasive
tools, can compete well with liver biopsy where the diag-
nosis of cirrhosis or advanced ﬁbrosis is concerned.
In contrast to Poynard et al. we do not believe that a
spectrum bias due to diﬀerent prevalence of stages in dif-
ferent populations can explain the decrease in the AUR-
OC when changing the deﬁnition of diseased liver or for
distinguishing between two adjacent ﬁbrosis stages. In
fact, any comparison of surrogate markers restricted
to two stages eliminated this spectrum bias! [4]. The
explanation for the low performance of markers for
distinguishing between two adjacent stages is lack of
accuracy, which leads us to reinforce our claim that sur-
rogate markers cannot be used for adequate monitoring
of individual ﬁbrosis staging.
Poynard et al. suggest that validation of non-invasive
test of ﬁbrosis and comparison with histological staging
with biopsy should rely on clinical endpoints. This is of
course ideal and surely adequate for any test that evalu-
ates ﬁbrosis independently of histology. Such is the case
for imaging techniques or assessment of liver stiﬀness.
This remark is less relevant when considering serum
markers of ﬁbrosis. The choice of blood tests included
in the marker’s formulas and their respective weights
in the algorithm are deﬁned through the prism of histo-
logic assessment of ﬁbrosis with liver biopsy. In this sit-
uation, liver biopsy is by deﬁnition the gold standard of
the serum markers and any weakness of the biopsy will
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